After a difficult nine months, Gerresheimer AG has reported a 4.7% increase in revenues for its 2017 Q4, the company announced.
Though the company saw organic growth of 6.7% for Q4, its financial year 2017 ended with a 2% decrease in revenues (to € 1,348.3 million). Gerresheimer cited market uncertainty, particularly in the US (the world’s largest pharmaceuticals market) for the decrease.
Related: Gerresheimer Debuts New Packaging Designs
“The financial year 2017 was characterized by uncertainty in the pharma and healthcare markets relevant to us,” said CFO and speaker of the management board Rainer Beaujean. “Growth in the global pharma market slowed considerably in 2017. Despite a slight decrease in revenues, we were able to raise profitability. We are consequently proposing an increased dividend. We are confident that we can grow sustainably and profitably in the coming years and further expand our strong position in the markets for pharmaceuticals, healthcare and cosmetics. We have taken important steps in this direction and set our strategic priorities for the years ahead.”
